dr. mcdermott on tki/immunotherapy combinations in rcc
Published 4 years ago • 144 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:35
dr. grigg on immunotherapy/tki combinations in rcc
-
3:15
a novel approach: tki/i-o combinations in rcc
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
0:45
dr. mcdermott on the role of vegf targeted therapy in rcc
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
0:59
dr. alva on tki monotherapy and combinations for rcc
-
5:15
favorable-risk rcc: frontline vegf tki/io combinations
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:15
immunotherapy/tki combinations in advanced rcc
-
1:08
mcdermott: immunotherapy agents in renal cell carcinoma
-
6:38
rcc: following patients on immunotherapy vs tki therapy
-
4:18
mrcc: how an approved i-o regimen impacts treatment